19 results about "Antibody-Producing Cells" patented technology

Methods are described herein for screening an antibody producing cell within a microfluidic environment. The antibody producing cell may be a B cell lymphocyte, which may be a memory B cell or a plasma cell. An antigen of interest may be brought into proximity with the antibody producing cell and binding of the antigen by an antibody produced by the antibody producing cell may be monitored. Methods of obtaining a sequencing library from an antibody producing cell are also described.

Disclosed herein are methods for detecting cells expressing antibody molecules on the cell surface that bind to a targeted antigen without competing with one or more binding partners of the target antigen. Also disclosed herein are methods for detecting and differentiating cells expressing antibody molecules on the cell surface to a target antigen that are non-competing with one or more binding partners, from cells expressing antibody molecules to a target antigen that block binding by a binding partner. The methods disclosed herein allow for enrichment and isolation of cells expressing antibody molecules on the cell surface to a target antigen that are non-competing with one or more binding partners, and cells expressing antibody molecules on the cell surface to a target antigen that block binding by a binding partner.

A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.

A method is derived for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.

Disclosed herein is a method for obtaining antibody-producing cells that express antibody molecules exhibiting high binding affinity to an antigen, comprising: contacting a population of antibody-producing cells, including cells expressing antibody molecules against an antigen on their cell surface, with a first labeled form of the antigen to enable the antigen to bind to antibody molecules on the cell surface; subsequently contacting the cells with (i) an unlabeled form of the antigen, (ii) a second labeled form of the antigen, or (iii) both the unlabeled and second labeled forms of the antigen; and collecting cells that remain bound to the first labeled form of the antigen, thereby obtaining cells that express antibody molecules with high affinity to the antigen. This method makes it possible to obtain cells expressing high-affinity antibody molecules from a pool of antibody-producing cells expressing antibody molecules with different affinities.

Disclosed herein are methods for detecting cells expressing antibody molecules on the cell surface that bind to a targeted antigen without competing with one or more binding partners of the target antigen. Also disclosed herein are methods for detecting and differentiating cells expressing antibody molecules on the cell surface to a target antigen that are non-competing with one or more binding partners, from cells expressing antibody molecules to a target antigen that block binding by a binding partner. The methods disclosed herein allow for enrichment and isolation of cells expressing antibody molecules on the cell surface to a target antigen that are non-competing with one or more binding partners, and cells expressing antibody molecules on the cell surface to a target antigen that block binding by a binding partner.

AL amyloidosis is treated using a combination of monoclonal antibodies against immunoglobulin light chains and immunoglobulin light chain aggregates with CD38 cell membrane molecules on antibody producing cells and other immune cells.

Disclosed are methods for obtaining cells that express antibodies that bind transmembrane proteins, methods for generating antibodies from such cells, antibodies to transmembrane proteins and fragments thereof, and nucleic acids encoding the antibodies. More particularly, the disclosure relates to methods for obtaining antibody-producing cells that express an antibody that binds to a transmembrane protein based on the use of lipid bilayer-membrane scaffold protein complexes to present transmembrane protein antigens to cells.

A biocompatible polymer composition having excellent handling properties that serves as a protein stabilizer having excellent protein stabilizing performance, a blocking agent having an excellent sensitizing effect, and a cell culture medium additive capable of culturing antibody-producing cells at excellent antibody productivity and cell activity is provided. Provided is a biocompatible polymer composition that contains a vinyl polymer (A) having an amine oxide group and a mass-average molecular weight of 5,000 or more and water, the surface tension of a 1% aqueous solution of which at 25° C. is 30-50 dyne / cm.

The invention discloses a probiotic composition and application thereof in treatment of immune diseases. The probiotic composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of probiotics, 5 to 15 parts of black garlic extract, 1 to 5 parts of eucheuma gelatinae polysaccharide and 0.5 to 1 part of stevioside. The probiotic composition disclosed by the invention has good acid-resistant and cholate-resistant activity, can increase the generation amount of B cells of antibody production cells of normal mice, can improve the antibody level of the normal mice, and has an enhancement effect on the humoral immune function of the normal mice.

To provide a treatment of AL amyloidosis by combination of a monoclonal antibody to an immunoglobulin light chain and a monoclonal antibody to a CD38 cell membrane molecule on antibody-producing cells or other immune cells.SOLUTION: Disclosed is a treatment of AL amyloidosis by combination of a monoclonal antibody against an immunoglobulin a light chain and aggregates thereof and a monoclonal antibody against a CD38 cell membrane molecule on antibody-producing or other immune cells. Typically, the effective dosage of these antibodies is effective to achieve an improvement in both hematologic and cardiac or other organ function. The dosage may be effective to achieve an improvement in both hematologic and organ function, for example, cardiac function.SELECTED DRAWING: None

Disclosed are methods for obtaining cells that express antibodies that bind transmembrane proteins, methods for generating antibodies from such cells, antibodies to transmembrane proteins and fragments thereof, and nucleic acids encoding the antibodies. More particularly, the disclosure relates to methods for obtaining antibody-producing cells that express an antibody that binds to a transmembrane protein based on the use of lipid bilayer-membrane scaffold protein complexes to present transmembrane protein antigens to cells.

The present invention aims to provide a method for immortalizing antibody-producing cells and the immortalized transformed cells obtained by this method. The present invention relates to a method for manufacturing immortalized cells, which involves introducing one or more genes selected from the group consisting of the SV40T antigen gene, the Bcl-2 family gene, and the Myc family gene and the Cyclin D family gene into non-immortalized antibody-producing cells. The present invention also relates to a method for manufacturing immortalized antibody-producing cells, which involves collecting antibody-producing cells from mammals, performing primary culture, and introducing one or more genes selected from the group consisting of the SV40T antigen gene, the Bcl-2 family gene, and the Myc family gene and the Cyclin D family gene into the obtained primary antibody-producing cells to create immortalized antibody-producing cells.

Provided are: a biocompatible polymer composition having excellent handling properties, which can be used as a protein stabilizer having excellent protein stabilizing ability, a blocking agent having excellent sensitizing effect, and a cell culture medium additive capable of culturing antibody-producing cells having excellent antibody producibility and cell viability; provided is a biocompatible polymer composition which contains water and a vinyl polymer (A) having an amine oxide group and a mass average molecular weight of 5,000 or more, and which has a surface tension of 30-50 dyn / cm at 25 DEG C in a 1% aqueous solution.

Cell fusion techniques have been used to produce hybrids between myeloma cells and antibody-producing cells. The hybrid lines derived are permanently adapted to grow in tissue culture and are capable of inducing antibody-producing tumors in mice.Spleens from mice immunized against sheep red blood cells (SRBC) were fused to an 8-azaguanine-resistant clone (X63-Ag8) of MOPC 21 myeloma. Over 50% of the derived hybrid lines produce and secrete immunoglobulins different from the MOPC 21 myeloma. About 10% of the hybrid lines exhibit anti-SRBC activity. The high proportion of antibody-producing hybrids suggests that the fusion involves a restricted fraction of the spleen cell population, probably cells committed to antibody production.In order to avoid the presence of the MOPC 21 heavy chain in the specific hybrids, another myeloma cell line (NSI / Ag4-1) has been used. This is a nonsecreting variant of the MOPC 21 myeloma which does not express heavy chains.Three anti-SRBC (probably of the μ, γ2b and γ1 classes, respectively) and two anti-2,4,6-trinitrophenyl (of the μ class antibody-producing hybrids have been repeatedly cloned. By random selection and by selection of specific clones according to their lytic activity (clone plaque selection), a number of different lines have been constructed. Such lines express different combinations of the four possible chains of each hybrid line: the myeloma γ and k chains and the specific antibody heavy and light chains. In three cases (Sp1, Sp2 and Sp7) it is shown that only the specific H and L combination has activity and that the myeloma chains are unable to substitute for them. In most cases lines have been derived which no longer express the MOPC 21 chains but only the specific antibody chains.

Disclosed herein is a method for obtaining an antibody-producing cell that expresses an antibody molecule that exhibits a high binding affinity to an antigen, the method comprises: contacting a population of antibody-producing cells encompassing cells expressing an antibody molecule against the antigen on a cell surface with a first labeled form of the antigen to allow the antigen to bind to the antibody molecule on the cell surface, subsequently contacting the cell with (i) an unlabeled form of the antigen, (ii) a second labeled form of the antigen, or (iii) the unlabeled form of the antigen and the second labeled form of the antigen; and collecting the cells that remain bound to the first labeled form of the antigen, thereby obtaining a cell that expresses a high affinity antibody molecule against the antigen. The method of the invention allows cells expressing high affinity antibody molecules to be obtained from antibody-producing cell pools expressing antibody molecules having different affinity.

An object of the present invention is to provide a method for immortalizing an antibody-producing cell; and an immortalized transformed cell obtained by the method. The invention relates to a method for producing an immortalized cell, the method including introducing SV40 T antigen gene, genes of Bcl-2 family, and one or more genes selected from the group consisting of genes of Myc family and genes of cyclin D family into a non-immortalized antibody-producing cell to produce an immortalized cell; and a method for producing an immortalized antibody-producing cell, the method including collecting an antibody-producing cell from a mammal and subjecting the cell to primary culture; and introducing one or more genes selected from the group consisting of SV40 T antigen gene, genes of Bcl-2 family, genes of Myc family, and genes of cyclin D family into a primary antibody-producing cell thus obtained to produce an immortalized antibody-producing cell.

To provide an insulin amyloid polymerized protein, an antibody, antibody-producing B cells and a medical composition capable of effectively preventing and treating Alzheimer type dementia with little side effects. An insulin amyloid polymerized protein is collected from a patient with Alzheimer type dementia to which insulin has been administered for use in the treatment of the patient. An insulin amyloid polymerized protein composition for use in the treatment of a patient with Alzheimer type dementia, wherein an insulin amyloid polymerized protein is obtained by chemically bonding insulin and amyloid. Also provided are an antibody therefor, antibody-producing B cells, and a medical composition.

The purpose of the present invention is to provide a method for causing cell immortalization of an antibody, and an immortalized transformed cell obtained by the method. The present invention relates to: a method for producing an immortalized cell by introducing, into a non-immortalized antibody-producing cell, an SV40T antigen gene, a Bcl-2 family gene, and one or more genes selected from the group consisting of a Myc family gene and a Cyclin D family gene; the invention also relates to a manufacturing method of the immortalized antibody producing cell. An immortalized antibody-producing cell is produced by collecting an antibody-producing cell from a mammal, performing primary culture, and introducing, into the obtained primary antibody-producing cell, an SV40T antigen gene, a Bcl-2 family gene, and one or more genes selected from the group consisting of a Myc family gene and a Cyclin D family gene.